Table 3.
Comparisons of clinical and outcome profiles in polyarteritis nodosa from various case series with different hepatitis B virus-infected frequencies
|
Source of cases
|
No/age1 F%
|
HBV status
|
Fever
|
AM
|
Skin
|
PN
|
GI
|
Renal
|
TestisM%
|
Therapy
|
Death
|
| Taiwan | 12/31, 67% | 0% | 67% | 58% | 75% | 42% | 50% | 75% | 50% | Az, Cs, Cy, Bio | 33% |
| United Kingdom | 17/49, 24% | 31% | 76% | 77% | 65% | 59% | 65% | 77% | NA | Cs, Is | 38% |
| United States | 53/54, 34% | 11% | 31% | 55% | 58% | 60% | 25% | 66% | NA | Cs, Cy | 42% |
| Canada | 45/54, 47% | 19% | 63% | 51% | 44% | 51% | 53% | 44% | 4% | Cs, Cy | 53% |
| South Korea | 27/47, 37% | 56% | 52% | 30% | 44% | 63% | 48% | 48% | 24% | Az, Cs, Cy, Is | 15% |
| France | 348/51,37% | 35% | 64% | 59% | 50% | 74% | 38% | 51% | 17% | Av, Cs, Cy, Is | 25% |
| India | 27/38, 26% | 26% | 52% | 37% | 37% | 82% | 30% | 59% | 30% | Av, Az, Cs, Cy | 11% |
1
Mean age at disease diagnosis. AM: Articulomuscular; Az: Azathioprine; Av: Antiviral agent; Bio: Biologics; Cs: Corticosteroids; Cy: Cyclophosphamide; F: Female; GI: Gastrointestinal; Is: Immunosuppressive agent, M: Male; NA: Not available; PN: Peripheral neuropathy.